Towards Better Pharmaceutical Provision in Europe-Who Decides the Future?

Significant progress has been achieved in human health in the European Union in recent years. New medicines, vaccines, and treatments have been developed to tackle some of the leading causes of disease and life-threatening illnesses. It is clear that investment in research and development (R&D)...

Full description

Saved in:
Bibliographic Details
Published in:Healthcare (Basel) 2022-08, Vol.10 (8), p.1594
Main Authors: Horgan, Denis, Spanic, Tanja, Apostolidis, Kathi, Curigliano, Giuseppe, Chorostowska-Wynimko, Joanna, Dauben, Hans-Peter, Lal, Jonathan A, Dziadziuszko, Rafal, Mayer-Nicolai, Christine, Kozaric, Marta, Jönsson, Bengt, Gutierrez-Ibarluzea, Iñaki, Fandel, Marie-Helene, Lopert, Ruth
Format: Article
Language:English
Subjects:
access
Citation management software
Coronaviruses
COVID-19
Efficiency
Forecasts and trends
Health care industry
innovation
Innovations
Interest groups
Laws, regulations and rules
Legislation
Medical screening
Pandemics
Patients
personalized medicine
pharmaceutical legislation
Pharmaceuticals
Precision medicine
Public health
Public policy
Quality management
Quality of life
security of supply
unmet medical need
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Significant progress has been achieved in human health in the European Union in recent years. New medicines, vaccines, and treatments have been developed to tackle some of the leading causes of disease and life-threatening illnesses. It is clear that investment in research and development (R&D) for innovative medicines and treatments is essential for making progress in preventing and treating diseases. Ahead of the legislative process, which should begin by the end of 2022, discussions focus on how Europe can best promote the huge potential benefits of new science and technology within the regulatory framework. The challenges in European healthcare were spelled out by the panellists at the roundtable organised by European Alliance for Personalised Medicine (EAPM). Outcomes from panellists' discussions have been summarized and re-arranged in this paper under five headings: innovation, unmet medical need, access, security of supply, adapting to progress, and efficiency. Some of the conclusions that emerged from the panel are a call for a better overall holistic vision of the future of pharmaceuticals and health in Europe and a collaborative effort among all stakeholders, seeing the delivery of medicines as part of a broader picture of healthcare.
ISSN:2227-9032
2227-9032
DOI:10.3390/healthcare10081594